Diagnostic Department, University Hospital of Geneva, Geneva, Switzerland.
Medicine Department, University Hospital of Geneva, Geneva, Switzerland.
Bone Marrow Transplant. 2022 Sep;57(9):1405-1410. doi: 10.1038/s41409-022-01737-z. Epub 2022 Jun 25.
ABO-incompatible allogeneic hematopoietic stem cell transplantation (HSCT) can be complicated by poor red cell engraftment and hemolysis, both mediated by isoagglutinins. Anecdotally, isoagglutinins indicates an activation of donor's immunity or even relapse. Consequently, the routine monitoring of isoagglutinins could help physicians to predict the risk of complications. The purpose of this study is to investigate the time to disappearance and appearance of isoagglutinins after ABO-incompatible allogeneic HSCT. In a one-year follow-up, data of 136 ABO-incompatible hematopoietic stem cell (HSC) allogeneic transplanted patients were studied, of which 60 had major, 61 minor and 15 bidirectional incompatibility. Survival analyses were conducted and association with hematological diseases, HLA-compatibility and transplantation strategy was investigated. We observed a disappearance of isoagglutinin A in 82.0% of cases at one year with a median and 75th percentile of 38.4 and 138.6 days, respectively. For isoagglutinin B, these same values were 96.4%, 15.9 and 29.1 days, respectively. The appearance of isoagglutinin A occurred in 10.7% of cases. Disappearance of isoagglutinin A was significantly slower in patients with myeloid diseases compared to other diseases. The results of this study provide useful values to detect early risks of preventable immunohematological complications and possibly, in exceptional cases, relapse.
ABO 不相容的异基因造血干细胞移植(HSCT)可并发红细胞植入不良和溶血,两者均由同种异型抗体介导。据报道,同种异型抗体表明供体的免疫激活,甚至复发。因此,常规监测同种异型抗体有助于医生预测并发症的风险。本研究旨在探讨 ABO 不相容异基因 HSCT 后同种异型抗体的消失和出现时间。在为期一年的随访中,研究了 136 例 ABO 不相容造血干细胞(HSC)异基因移植患者的数据,其中 60 例为主要不相容,61 例为次要不相容,15 例为双向不相容。进行了生存分析,并调查了与血液系统疾病、HLA 相容性和移植策略的关联。我们观察到,1 年后有 82.0%的病例同种异型抗体 A 消失,中位数和第 75 百分位数分别为 38.4 和 138.6 天。对于同种异型抗体 B,这些值分别为 96.4%、15.9 和 29.1 天。10.7%的病例出现同种异型抗体 A。与其他疾病相比,骨髓疾病患者同种异型抗体 A 的消失明显较慢。本研究的结果为早期发现可预防的免疫血液学并发症风险提供了有用的价值,在特殊情况下,可能为复发提供了价值。